DanielMorgenszternMD

Oncology • Saint Louis, MO

Associate Professor, Washington University School of Medicine, St. Louis, MO.

Join to view full profile

Dr. Morgensztern is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Morgensztern's full profile

Already have an account?

Office
4921 Parkview Pl
# Dv
Saint Louis, MO 63110
Phone+1 800-647-2098

Fax+1 314-362-3192

Education & Training

University of Miami/Jackson Health SystemResidency, Internal Medicine, 1998 - 2001
Tech- Ed Fndn Souza Marques Sch MedClass of 1995

Certifications & Licensure

MO State Medical License 2013 - 2026
CT State Medical License 2010 - 2013
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Erlotinib and Avastin in Patients With Cancer of the Esophagus or Gastroesophageal Junction Start of enrollment: 2007 Mar 01
Terminated
Phase 2
Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer Start of enrollment: 2013 Sep 01
Completed
Phase 2
Multicenter Study of Rociletinib Administered to Patients With Previously Treated Mutant EGFR Non-small Cell Lung Cancer Start of enrollment: 2014 Jun 16
Terminated
Phase 2
Hypofractionated Proton Beam Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Stage II-III Non-Small Cell Lung Cancer Start of enrollment: 2014 May 22
Completed
Phase 1
Pazopanib in Molecularly Selected Patients With Advanced NSCLC Start of enrollment: 2015 Apr 27
Terminated
Phase 2
Genomic Landscape of EGFR Mutant NSCLC Prior to Erlotinib and at the Time of Disease Progression Start of enrollment: 2015 Apr 30
Terminated
A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer Start of enrollment: 2015 Apr 15
Completed
Phase 1, Phase 2
Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer Start of enrollment: 2016 Jan 25
Completed
Phase 2
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Role of Circulating Tumor DNA (ctDNA) From LIquid Biopsy in Early Stage NSCLC Resected Lung Tumor Investigation Start of enrollment: 2018 Jun 01
Terminated
Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC Start of enrollment: 2019 Jun 05
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

Post-Operative Radiation Therapy for Non-Small Cell Lung Cancer Patients With Higher Positive to Examined Lymph Node Ratio is Associated With Improved Overall Survival.
Temitope Agabalogun, Brendan T. Heiden, M.B. Spraker, S.N. Badiyan, G.R. Vlacich
International Journal of Radiation Oncology Biology Physics. 2021-11-01
KEYLYNK-012: A Phase 3 Study of Pembrolizumab With Concurrent Chemoradiation Therapy (CCRT) Followed by Pembrolizumab With or Without Olaparib vs. CCRT Followed by Dur...
Salma K. Jabbour, Byoung Chul Cho, Emilio Bria, Terufumi Kato, Jaishree Bhosle
International Journal of Radiation Oncology Biology Physics. 2021-11-01
Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer.
David E Gerber, D Ross Camidge, Daniel Morgensztern, Jeremey Cetnar, Ronan J Kelly
Lung cancer (Amsterdam, Netherlands). 2019-11-19

Journal Articles

Recurrent WNT Pathway Alterations Are Frequent in Relapsed Small Cell Lung Cancer
Saiama N. Waqar, Daniel Morgensztern, Robert S. Fulton, Ramaswamy Govindan, Nature

Lectures

Viagenpumatucel-L (HS-110) plus nivolumab in patients with advanced non-small cell lung cancer (NSCLC) after checkpoint inhibitor treatment failure.
2019 ASCO Annual Meeting - 6/1/2019
Multicenter phase II trial of RRx-001 in previously treated SCLC.
2019 ASCO Annual Meeting - 6/1/2019
Yale Cancer Center Evening Oncology Series: Lung Cancer
Yale CME, New Haven, Connecticut - 5/10/2012

Authored Content

Early Mortality in Patients Undergoing Adjuvant Chemotherapy for Non-Small-Cell Lung CancerFebruary 2018

Press Mentions

Safety and Efficacy of Zimberelimab (AB122) in Combination with Domvanalimab (AB154) and Etrumadenant (AB928) in Patients with Previously Treated Non-Small Cell Lung CancerMarch 10th, 2021
Adding a Vaccine to Immunotherapy in Lung Cancer: Will It Improve Outcomes?March 4th, 2019
Heat Biologics, Inc. (NASDAQ:HTBX) Files an 8-K Regulation FD DisclosureFebruary 28th, 2019
Join now to see all